URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$44.09
−1.76%0
Insider buys (3m)
4
Insider sells (3m)
-$3.7M
Net value (3m)
+62.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Robinson James A. Jr. · director | M-Exempt | 2,000 | $0.00 |
| Aug 24, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 60,677 | $47 |
| Jul 10, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 10,000 | $40 |
| Jun 24, 2026 | Belldegrun Arie · director | A-Award | 20,000 | $35 |
| Jun 24, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 10,000 | $35 |
| Jun 24, 2026 | Wildman Daniel George · director | A-Award | 10,000 | $35 |
| Jun 24, 2026 | Wildman Daniel George · director | A-Award | 8,000 | $0.00 |
| Jun 24, 2026 | Robinson James A. Jr. · director | A-Award | 10,000 | $35 |
| Jun 24, 2026 | Robinson James A. Jr. · director | A-Award | 8,000 | $0.00 |
| Jun 24, 2026 | Holden Stuart · director | A-Award | 20,000 | $35 |
| Jun 24, 2026 | BUTITTA CYNTHIA M · director | A-Award | 10,000 | $35 |
| Jun 24, 2026 | BUTITTA CYNTHIA M · director | A-Award | 8,000 | $0.00 |
| Jun 24, 2026 | WEN LEANA · director | A-Award | 10,000 | $35 |
| Jun 24, 2026 | WEN LEANA · director | A-Award | 8,000 | $0.00 |
| Jun 9, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 5,222 | $27 |
| Jun 9, 2026 | Schoenberg Mark · officer: Chief Medical Officer | M-Exempt | 10,000 | $0.00 |
| May 27, 2026 | Robinson James A. Jr. · director | M-Exempt | 2,000 | $0.00 |
| May 11, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 10,000 | $30 |
| Feb 27, 2026 | Robinson James A. Jr. · director | M-Exempt | 2,000 | $0.00 |
| Feb 19, 2026 | Barrett Elizabeth A. · officer: Chief Executive Officer | A-Award | 153,195 | $0.00 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | Sale | 2,654 | $20 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | Sale | 3,217 | $20 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | M-Exempt | 3,333 | $0.00 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | A-Award | 32,609 | $0.00 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | M-Exempt | 6,667 | $0.00 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | Sale | 1,608 | $20 |
| Feb 11, 2026 | Smith Jason Drew · officer: General Counsel | M-Exempt | 5,500 | $0.00 |
| Feb 4, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 1,844 | $20 |
| Feb 4, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 1,843 | $20 |
| Feb 4, 2026 | Schoenberg Mark · officer: Chief Medical Officer | Sale | 3,686 | $20 |
Institutional positioning
13F filings over the trailing two quarters
New 33Increased 52Reduced 53Sold out 170
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RTW INVESTMENTS, LP | Unchanged | 4,543,895 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 2,845,567 | May 13, 2026 |
| TORONTO DOMINION BANK | New Position | 2,616,714 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 2,560,038 | May 15, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | New Position | 2,247,393 | May 15, 2026 |
| JEFFERIES FINANCIAL GROUP INC. | Unchanged | 2,199,652 | May 8, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Reduced | 1,703,949 | May 15, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Increased | 1,673,420 | May 15, 2026 |
| SG AMERICAS SECURITIES, LLC | Increased | 1,657,846 | Apr 16, 2026 |
| AMERICAN CENTURY COMPANIES INC | Increased | 1,637,570 | May 15, 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | Reduced | 1,503,045 | May 14, 2026 |
| OPALEYE MANAGEMENT INC. | Increased | 1,430,000 | May 15, 2026 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | Increased | 1,314,112 | May 15, 2026 |
| MENORA MIVTACHIM HOLDINGS LTD. | Unchanged | 1,152,531 | May 14, 2026 |
| D. E. SHAW & CO., INC. | Increased | 1,023,159 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 28, 2026